1. Toxicity from aluminium and iron: recognition, treatment and prevention;Kurtzman, N.A.;Semin Nephrol,1986
2. Design, properties and effective use of the oral chelator LI and other (x-ketohvdroxypyridines in the treatment of transfusional iron overload in thalassaemia;Kontoghiorghes, G.J.;Ann NY Acad Sci,1990
3. Long term trial with the oral iron chelator 1,2-diunethyl-3-hydroxypyrid-4-one (LI). (I) Iron chelation and metabolic studies. BrJ7 Haematol;Kontoghiorghes, G.J.; Bartlett, A.N.; Hoffbrand, A.V.; Goddard, J.G.; Sheppard, L.; Barr, J.; ct al;BrJ Haematol; LI (1,2-dimethyl-3-hydroxypyrid-4-one) for oral iron chelation in patients with 5 thalassaemia major,1990
4. Oral iron chelation with Ll;Agarwal, M.B.; Viswanathan, C.; Ramanathan, J.; Massil, D.E.; Shah, S.; Gupte, S.S.;Lancet,1990
5. Pharmacokinetic studies in humans with the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one;Kontoghiorghes, G.J.; Goddard, J.G.; Bartlett, A.N.; Sheppard, L.;Clin Pharmacol Ther,1990